- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02192593
Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations
March 3, 2017 updated by: Jennifer Gottlieb, Boston University Charles River Campus
Randomized Controlled Trial of Computerized Cognitive Behavioral Therapy for Auditory Hallucinations in Persons With Psychosis
This is a randomized controlled trial, examining the effects of a computerized, internet-based Cognitive Behavioral Therapy (CBT) Intervention for persons with a schizophrenia spectrum disorder who experience distressing auditory hallucinations (voices).
Participants are randomized to one of two conditions: either to receive the 10-session computer-based program on a weekly basis, or to their usual care at their mental health clinic.
This study takes place at Cambridge Health Alliance in Cambridge Massachusetts.
It is hypothesized that the participants who participate in the CBT program will have significant improvements in the severity of their auditory hallucinations, as well as their associated distress, compared to the participants receiving usual care.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02139
- Cambridge Health Alliance
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Participants will be on a stable dose of antipsychotic medication for the past 3 months.
- Schizophrenia-spectrum diagnosis, including schizophrenia, schizoaffective disorder, schizophreniform disorder, and psychosis, not otherwise specified.
- At least moderate severity on Brief Psychiatric Rating Scale (BPRS) hallucinations item.
- Naïve to CBTp for Auditory Hallucinations within the past 3 years.
- No current suicidal ideation or hospitalization within the past month.
- Reading level of at least 4th grade, as measured by the reading section of the Wide Range Achievement Test (WRAT)
- Current patient receiving care at Cambridge Health Alliance
Exclusion Criteria:
Terminal physical illness expected to result in the death of the study participant within one year.
- Primary diagnosis of dementia or a diagnosis of a psychiatric disorder secondary to a medical condition.
- Comorbid dementia (severe cognitive impairment) as indicated by a Mini-mental state examination score <24.
- Current active substance abuse or dependence with the need for specialized substance abuse services
- Does not speak English
- Does not achieve a 4th grade reading level as demonstrated on the Wide Range Achievement Test (WRAT)
- Has a legal guardian
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual Care
|
|
|
Experimental: Computer CBT
A 10-session computerized cognitive-behavioral therapy intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Psychiatric Rating Scale (BPRS)
Time Frame: Baseline, Post-Treatment, 3-Month Follow-up
|
Primary outcome is change in BPRS hallucinations item from baseline to post-treatment to 3 month follow-up.
This measure assesses severity of auditory hallucinations as well as overall psychiatric symptoms
|
Baseline, Post-Treatment, 3-Month Follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jennifer D Gottlieb, PhD, Boston University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
January 1, 2014
Study Completion (Actual)
February 1, 2015
Study Registration Dates
First Submitted
September 13, 2013
First Submitted That Met QC Criteria
July 15, 2014
First Posted (Estimate)
July 17, 2014
Study Record Updates
Last Update Posted (Actual)
March 6, 2017
Last Update Submitted That Met QC Criteria
March 3, 2017
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ComputerCBTPsychosis
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia, Schizoaffective Disorder
-
Teva Branded Pharmaceutical Products R&D LLCCompletedSchizophrenia, Schizoaffective DisorderUnited States
-
Hoffmann-La RocheTerminatedSchizophrenia, Schizoaffective DisorderUnited States, Spain, Japan, Ukraine
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompletedSchizophrenia and Schizoaffective DisorderHungary, United States, Argentina, Canada, Czech Republic, Estonia, France, Latvia, Lithuania
-
Central Institute of Mental Health, MannheimCompletedSchizophrenia, Schizoaffective DisorderGermany
-
Hoffmann-La RocheCompletedSchizophrenia, Schizoaffective DisorderUnited States, Japan, Ukraine, Russian Federation
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedSchizophrenia and Schizoaffective Disorder
-
University of Sao PauloUnknownSchizophrenia or Schizoaffective DisorderBrazil
-
Shu-Mei WangNot yet recruiting
Clinical Trials on Computer CBT
-
Hebrew University of JerusalemRecruitingObsessive-Compulsive DisorderIsrael
-
University of MinnesotaCompletedGeneralized Anxiety Disorder | Social Anxiety | Alcohol Use Disorder | Panic DisorderUnited States
-
iHope Network, Inc.UConn Health; Woburn Pediatric AssociatesCompletedMajor Depressive DisorderUnited States
-
Temple UniversityCompleted
-
University of LouisvilleUniversity of York; University of DenverCompletedDepressionUnited States
-
Indiana UniversityAmerican Heart AssociationCompletedDepression | Depressive Symptoms | Heart Disease | Coronary Artery Disease (CAD) | Cardiovascular Disease (CVD)United States
-
US Department of Veterans AffairsCompletedHeart Failure | Beta-blocker TreatmentUnited States
-
University of PennsylvaniaCompletedChronic Post-Surgical PainUnited States
-
Northwell HealthBoston University; University of Pittsburgh; Dartmouth-Hitchcock Medical CenterCompletedSchizophrenia | Schizoaffective Disorder | Psychosis NOSUnited States
-
Douglas Mental Health University InstituteCanadian Institutes of Health Research (CIHR)CompletedPsychosis | Social PhobiaCanada